Silent reactivation of Varicella Zoster virus in hemodialysis patients.

References

1. 1.↵
   1. Johnson RW,
   2. Wasner G,
   3. Saddier P,
   4. Baron R.

   Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007; 7: 1581-1595.

   OpenUrlCrossRefPubMed
2. 2.↵
   Varicellovirus - an overview | ScienceDirect Topics [Internet]. [cited 2024 Mar 3]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/varicellovirus
3. 3.↵
   1. Duncan CJA,
   2. Hambleton S.

   Varicella zoster virus immunity: A primer. J Infect 2015; 71: S47–S53.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Mahallawi WH,
   2. Alharbi WA,
   3. Aloufi SA,
   4. Ibrahim NA,
   5. Abdelrahman MM,
   6. Alhomayeed BA, et al.

   Declined humoral immunity of kidney transplant recipients to SARS-CoV-2 vaccines. Infect Drug Resist 2023; 16: 2829–2840.

   OpenUrlPubMed
5. 5.↵
   1. Alqahtani SAM,
   2. Mahallawi WH,
   3. Alomar S.

   Predicting immunogenicity of COVID-19 vaccines in hemodialysis patients with renal disease. Heliyon 2024; 10: e27594.

   OpenUrl
6. 6.↵
   1. Babel N,
   2. Hugo C,
   3. Westhoff TH.

   Vaccination in patients with kidney failure: lessons from COVID-19. Nat Rev Nephrol 2022; 18: 708–723.

   OpenUrlPubMed
7. 7.↵
   1. Gourishankar S,
   2. McDermid JC,
   3. Jhangri GS,
   4. Preiksaitis JK.

   Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4: 108–115.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Losappio V,
   2. Franzin R,
   3. Infante B,
   4. Godeas G,
   5. Gesualdo L,
   6. Fersini A, et al.

   Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay between Innate and Adaptive Immune Dysfunction. Int J Mol Sci 2020; 21: 3422.

   OpenUrlPubMed
9. 9.
   1. Al Kaabi N,
   2. Al Olama FMAS,
   3. Al Qaseer M,
   4. Al Ubaidani I,
   5. Dinleyici EC,
   6. Hayajneh WA, et al.

   The clinical and economic burden of varicella in the Middle East: a systematic literature review. Hum Vaccin Immunother 2019; 16: 21–32.

   OpenUrlPubMed
10. 10.↵
    1. Asada H.

    VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study. Vaccine 2019; 37: 6776–6781.

    OpenUrlPubMed
11. 11.↵
    1. Oxman MN.

    Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109: S13-S17.

    OpenUrlPubMed
12. 12.↵
    1. Freuer D,
    2. Linseisen J,
    3. Waterboer T,
    4. Pessler F,
    5. Guzmán CA,
    6. Wawro N, et al.

    Seropositivity of selected chronic infections and different measures of obesity. PLoS One 2020; 15: e0231974.

    OpenUrlPubMed
13. 13.
    1. Gershon AA,
    2. Gershon MD.

    Pathogenesis and current approaches to control of Varicella-Zoster virus infections. Clin Microbiol Rev 2013; 26: 728–743.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. de Jong MD,
    2. Weel JFL,
    3. Schuurman T,
    4. Wertheim-van Dillen PME,
    5. Boom R.

    Quantitation of Varicella-Zoster virus DNA in whole blood, plasma, and serum by PCR and Electrochemiluminescence. J Clin Microbiol 2000; 38: 2568–2573.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Gershon AA,
    2. Breuer J,
    3. Cohen JI,
    4. Cohrs RJ,
    5. Gershon MD,
    6. Gilden D, et al.

    Varicella zoster virus infection. Nat Rev Dis Primers 2015; 1: 15016.

    OpenUrlPubMed